Patient advocacy organizations have expressed concerns that recent tax cuts announced in the 2025 budget will not be sufficient to lower the high prices of medicines for cancer and rare diseases. Experts argue that more comprehensive measures are needed to make these critical drugs affordable for patients.
Patient advocacy groups say 2025 budget tax cuts won’t lower high prices of cancer and rare disease medicines, calling for broader reforms to improve affordability.
New Delhi – Patient advocacy groups have voiced their concerns regarding the recently announced tax cuts on medicines, stating that these measures will not effectively address the persistently high prices of drugs used to treat cancer and rare diseases. The groups emphasize that despite the government’s efforts in the 2025 budget to ease the financial burden on patients, the tax reductions alone are unlikely to make a significant impact on affordability.
The 2025 budget, presented earlier this week, proposed a reduction in taxes on certain pharmaceutical products as part of its broader strategy to support healthcare. However, representatives from various patient organizations warn that these cuts do not tackle the core issues driving the soaring costs of specialty medicines, including research and development expenses, limited competition, and pricing policies by pharmaceutical companies.
“While tax relief can marginally reduce the price tag on some medicines, the overall cost of cancer and rare disease treatments remains prohibitively high for many patients,” said Anjali Mehta, spokesperson for the National Patient Alliance. “We need more systemic reforms such as price regulation, incentivizing generic drug production, and increased government subsidies to truly make these medicines accessible.”
High prices for cancer and rare disease medicines have long been a challenge in India, impacting patient treatment outcomes and leading to significant out-of-pocket expenditure. According to recent studies, the median cost of cancer therapies often exceeds thousands of dollars per cycle, placing them out of reach for a majority of patients. Similarly, drugs for rare diseases, which affect fewer individuals, tend to be priced even higher due to the complexity and cost of development coupled with low market demand.
Pharmaceutical industry experts acknowledge the concerns but highlight the importance of tax revenues in supporting innovation and infrastructure. “Tax reductions can encourage lower prices to some extent, but sustainable affordability requires a multi-pronged approach involving government policies, industry collaboration, and increased access programs,” said Dr. Ravi Kumar, a healthcare economist.
In recent years, the government has introduced several initiatives aimed at improving access to essential medicines, including price caps under the National Pharmaceutical Pricing Authority (NPPA) and subsidies for select treatments. However, these measures have been met with mixed results, particularly in the specialty drug segment.
Advocacy groups recommend that policymakers consider implementing stricter price controls for high-cost specialty drugs, expanding insurance coverage for rare diseases, and fostering competition by expediting the approval of biosimilars and generics. They also stress the importance of involving patient voices in policy formulation to ensure that reforms address real-world challenges faced by those affected.
The government, in response, has acknowledged the complexities involved in balancing drug affordability with pharmaceutical innovation. Officials have indicated plans to engage with stakeholders to explore more comprehensive strategies to address these issues moving forward.
As the debate continues, patients and their families remain hopeful that future policies will better reflect their needs, ensuring access to life-saving treatments without undue financial hardship.
In conclusion, while the 2025 budget’s tax cuts on medicines represent a positive step towards easing healthcare costs, patient advocacy groups maintain that these measures are insufficient to significantly reduce the high prices of cancer and rare disease drugs. Achieving meaningful affordability will require targeted regulatory actions, expanded insurance frameworks, and collaborative efforts between the government, industry, and patient communities.
